Growing evidence showed that an NK-1R antagonist could disrupt the binding of substance P to NK-1R, which significantly improved the motor and cognitive outcomes and inhibited dyskinesia in a hemi-Parkinsonian rat model [27]. This evidence concerns the gene TAC1 and Dyskinesia.